Posted by Michael Wonder on 16 Apr 2023
Horizon Therapeutics announces FDA approval of an update to the indication language for Tepezza (teprotumumab-trbw) to specify its use in thyroid eye disease patients regardless of disease activity or duration
14 April 2023 - Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of thyroid eye disease.
Horizon Therapeutics today announced that the US FDA has approved an update to the Indications and Usage section of the Tepezza label to specify its use for the treatment of “Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
